Cargando…
LCC-09, a Novel Salicylanilide Derivative, Exerts Anti-Inflammatory Effect in Vascular Endothelial Cells
OBJECTIVE: Endothelial cell (EC) activation facilitates leukocyte adhesion to vascular walls, which is implicated in a variety of cardiovascular diseases and is a target for prevention and treatment. Despite the development of anti-inflammatory medications, cost-effective therapies with significant...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436973/ https://www.ncbi.nlm.nih.gov/pubmed/34526801 http://dx.doi.org/10.2147/JIR.S305168 |
_version_ | 1783752086821797888 |
---|---|
author | Angom, Ramcharan Singh Zhu, Jian Wu, Alexander T H Sumitra, Maryam Rachmawati Pham, Victoria Dutta, Shamit Wang, Enfeng Madamsetty, Vijay Sagar Perez-Cordero, Gabriel D Huang, Hsu-Shan Mukhopadhyay, Debabrata Wang, Ying |
author_facet | Angom, Ramcharan Singh Zhu, Jian Wu, Alexander T H Sumitra, Maryam Rachmawati Pham, Victoria Dutta, Shamit Wang, Enfeng Madamsetty, Vijay Sagar Perez-Cordero, Gabriel D Huang, Hsu-Shan Mukhopadhyay, Debabrata Wang, Ying |
author_sort | Angom, Ramcharan Singh |
collection | PubMed |
description | OBJECTIVE: Endothelial cell (EC) activation facilitates leukocyte adhesion to vascular walls, which is implicated in a variety of cardiovascular diseases and is a target for prevention and treatment. Despite the development of anti-inflammatory medications, cost-effective therapies with significant anti-inflammatory effects and lower organ toxicity remain elusive. The goal of this study is to identify novel synthetic compounds that inhibit EC inflammatory response with minimal organ toxicity. METHODS AND RESULTS: In this study, we discovered LCC-09, a salicylanilide derivative consisting of the functional fragment of magnolol, 2,4-difluorophenyl, and paeonol moiety of salicylate, as a novel anti-inflammatory compound in cultured ECs and zebrafish model. LCC-09 was shown to inhibit pro-inflammatory cytokine tumor necrosis factor-α (TNFα)-induced expression of adhesion molecules and inflammatory cytokines, leading to reduced leukocyte adhesion to ECs. Mechanistically, LCC-09 inhibits the phosphorylation of signal transducer and activator of transcription 1 (STAT1), TNFα-induced degradation of NF-κ-B Inhibitor-α (IκBα) and phosphorylation of NFκB p65, resulting in reduced NFκB transactivation activity and binding to E-selectin promoter. Additionally, LCC-09 attenuated TNFα-induced generation of reactive oxygen species in ECs. Molecular docking models suggest the binding of LCC-09 to NFκB essential modulator (NEMO) and Janus tyrosine kinase (JAK) may lead to dual inhibition of NFκB and STAT1. Furthermore, the anti-inflammatory effect of LCC-09 was validated in the lipopolysaccharides (LPS)-induced inflammation model in zebrafish. Our results demonstrated that LCC-09 significantly reduced the LPS-induced leukocyte recruitment and mortality of zebrafish embryos. Finally, LCC-09 was administered to cultured ECs and zebrafish embryos and showed minimal toxicities. CONCLUSION: Our results support that LCC-09 inhibits EC inflammatory response but does not elicit significant toxicity. |
format | Online Article Text |
id | pubmed-8436973 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-84369732021-09-14 LCC-09, a Novel Salicylanilide Derivative, Exerts Anti-Inflammatory Effect in Vascular Endothelial Cells Angom, Ramcharan Singh Zhu, Jian Wu, Alexander T H Sumitra, Maryam Rachmawati Pham, Victoria Dutta, Shamit Wang, Enfeng Madamsetty, Vijay Sagar Perez-Cordero, Gabriel D Huang, Hsu-Shan Mukhopadhyay, Debabrata Wang, Ying J Inflamm Res Original Research OBJECTIVE: Endothelial cell (EC) activation facilitates leukocyte adhesion to vascular walls, which is implicated in a variety of cardiovascular diseases and is a target for prevention and treatment. Despite the development of anti-inflammatory medications, cost-effective therapies with significant anti-inflammatory effects and lower organ toxicity remain elusive. The goal of this study is to identify novel synthetic compounds that inhibit EC inflammatory response with minimal organ toxicity. METHODS AND RESULTS: In this study, we discovered LCC-09, a salicylanilide derivative consisting of the functional fragment of magnolol, 2,4-difluorophenyl, and paeonol moiety of salicylate, as a novel anti-inflammatory compound in cultured ECs and zebrafish model. LCC-09 was shown to inhibit pro-inflammatory cytokine tumor necrosis factor-α (TNFα)-induced expression of adhesion molecules and inflammatory cytokines, leading to reduced leukocyte adhesion to ECs. Mechanistically, LCC-09 inhibits the phosphorylation of signal transducer and activator of transcription 1 (STAT1), TNFα-induced degradation of NF-κ-B Inhibitor-α (IκBα) and phosphorylation of NFκB p65, resulting in reduced NFκB transactivation activity and binding to E-selectin promoter. Additionally, LCC-09 attenuated TNFα-induced generation of reactive oxygen species in ECs. Molecular docking models suggest the binding of LCC-09 to NFκB essential modulator (NEMO) and Janus tyrosine kinase (JAK) may lead to dual inhibition of NFκB and STAT1. Furthermore, the anti-inflammatory effect of LCC-09 was validated in the lipopolysaccharides (LPS)-induced inflammation model in zebrafish. Our results demonstrated that LCC-09 significantly reduced the LPS-induced leukocyte recruitment and mortality of zebrafish embryos. Finally, LCC-09 was administered to cultured ECs and zebrafish embryos and showed minimal toxicities. CONCLUSION: Our results support that LCC-09 inhibits EC inflammatory response but does not elicit significant toxicity. Dove 2021-09-08 /pmc/articles/PMC8436973/ /pubmed/34526801 http://dx.doi.org/10.2147/JIR.S305168 Text en © 2021 Angom et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Angom, Ramcharan Singh Zhu, Jian Wu, Alexander T H Sumitra, Maryam Rachmawati Pham, Victoria Dutta, Shamit Wang, Enfeng Madamsetty, Vijay Sagar Perez-Cordero, Gabriel D Huang, Hsu-Shan Mukhopadhyay, Debabrata Wang, Ying LCC-09, a Novel Salicylanilide Derivative, Exerts Anti-Inflammatory Effect in Vascular Endothelial Cells |
title | LCC-09, a Novel Salicylanilide Derivative, Exerts Anti-Inflammatory Effect in Vascular Endothelial Cells |
title_full | LCC-09, a Novel Salicylanilide Derivative, Exerts Anti-Inflammatory Effect in Vascular Endothelial Cells |
title_fullStr | LCC-09, a Novel Salicylanilide Derivative, Exerts Anti-Inflammatory Effect in Vascular Endothelial Cells |
title_full_unstemmed | LCC-09, a Novel Salicylanilide Derivative, Exerts Anti-Inflammatory Effect in Vascular Endothelial Cells |
title_short | LCC-09, a Novel Salicylanilide Derivative, Exerts Anti-Inflammatory Effect in Vascular Endothelial Cells |
title_sort | lcc-09, a novel salicylanilide derivative, exerts anti-inflammatory effect in vascular endothelial cells |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436973/ https://www.ncbi.nlm.nih.gov/pubmed/34526801 http://dx.doi.org/10.2147/JIR.S305168 |
work_keys_str_mv | AT angomramcharansingh lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells AT zhujian lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells AT wualexanderth lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells AT sumitramaryamrachmawati lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells AT phamvictoria lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells AT duttashamit lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells AT wangenfeng lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells AT madamsettyvijaysagar lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells AT perezcorderogabrield lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells AT huanghsushan lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells AT mukhopadhyaydebabrata lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells AT wangying lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells |